Authors
Latest:
Lymph nodes in bladder cancer: Past, present, and future"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Latest:
Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation TherapyDr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
AACU 2024 Advocacy Summit & Annual MeetingThis year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.
Latest:
Key Takeaways on the Evolving NMIBC Treatment LandscapeThe panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Distinguishing between malignant and benign renal masses"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.
Latest:
Optimization of Genetic Testing for mCRPCJason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Latest:
Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidanceUrinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
The American Board of Urology: Considerations for the urologist in career transitions"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.
Latest:
UCI receives renewal as Orange County’s only federally designated comprehensive cancer centerThe National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation
Latest:
GNRH agonists vs antagonists in prostate cancer: How to chooseMany factors play into decision-making process when weighing agents.
Latest:
Looking Ahead: Image-Guided Diagnostic ToolsKyrollis Attalla, MD, remarks on emerging imaging technologies for patients with prostate cancer and the growing pool of candidates for focal therapy.
Latest:
Legislative efforts to eliminate barriers to prostate cancer screening ramp up"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.
Latest:
Erdafitinib nears EU approval for FGFR3-positive urothelial carcinomaThe positive CHMP opinion is supported by findings from cohort 1 of the phase 3 THOR trial.
Latest:
MIPS success: What specialists need to know"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.
Latest:
Recognizing hereditary syndromes in renal cell carcinomaPatients may require specific diagnostic, surveillance, and therapeutic management.
Latest:
Low-intensity shockwave therapy, plasma injections efficacious for erectile dysfunctionSMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.
Latest:
EBRT not linked to increased hematological toxicity for mCRPC treated with Ra-233Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Considerations for choosing an AI scribe toolAI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.
Latest:
Key Takeaways on the Evolving NMIBC Treatment LandscapeThe panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet NeedsIn this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
